Intravitreal bevacizumab monotherapy for retinopathy of prematurity

Basit Öğe Kaydı
dc.contributor.authorSahin, Alparslan
dc.contributor.authorSahin, Muhammed
dc.contributor.authorCingu, Abdullah Kuersat
dc.contributor.authorCinar, Yasin
dc.contributor.authorTurkcu, Fatih Mehmet
dc.contributor.authorYuksel, Harun
dc.contributor.authorKaya, Savas
dc.date.accessioned2024-04-24T17:11:49Z
dc.date.available2024-04-24T17:11:49Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackgroundThe aim of this study was to evaluate the treatment outcomes of intravitreal bevacizumab (IVB) injections, used as a monotherapy in type 1 retinopathy of prematurity (ROP). MethodsA retrospective chart review was performed for 17 type 1 ROP patients (34 eyes), who had IVB injection between July 2011 and June 2012. Birthweight, gestational age at birth, stage and location of ROP, IVB injection time, time of complete retinal vascularization, and additional treatments if needed, were noted. A total of 0.625mg (0.025mL) bevacizumab was injected intravitreally. ResultsThirty eyes of 17 patients with type 1 ROP enrolled in the study were treated with IVB injection. Of them seven had aggressive posterior-ROP, six had stage 2 ROP, and four had stage 3 ROP. The mean gestational age was 28.44 weeks (range, 26-31 weeks); and the mean birthweight was 1151.88g (range, 600-1600g). The mean age for IVB injection was 35.47 weeks. The mean full retinal vascularization time was 136.6 26.6 days. The mean follow-up time was 285.3 +/- 70 days. ROP was regressed and retinal vascularization was completed in all cases except one eye, which had threshold disease. ConclusionIVB injection, used as a monotherapy, is an effective treatment approach in patients with type 1 ROP. Timely treatment of stage 2 and early stage 3 ROP in which disease progression was observed, prevents vitreoretinal membrane formation in posterior disease. Further studies need to be performed to determine the safety of IVB injection.en_US
dc.identifier.doi10.1111/ped.12124
dc.identifier.endpage603en_US
dc.identifier.issn1328-8067
dc.identifier.issn1442-200X
dc.identifier.issue5en_US
dc.identifier.pmid23659781
dc.identifier.scopus2-s2.0-84886091310
dc.identifier.scopusqualityQ3
dc.identifier.startpage599en_US
dc.identifier.urihttps://doi.org/10.1111/ped.12124
dc.identifier.urihttps://hdl.handle.net/11468/17733
dc.identifier.volume55en_US
dc.identifier.wosWOS:000329507700021
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherWiley-Blackwellen_US
dc.relation.ispartofPediatrics International
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBevacizumaben_US
dc.subjectMonotherapyen_US
dc.subjectRetinopathy Of Prematurityen_US
dc.titleIntravitreal bevacizumab monotherapy for retinopathy of prematurityen_US
dc.titleIntravitreal bevacizumab monotherapy for retinopathy of prematurity
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu